| ДУЭЛЬ-ХСН | ДиУретическая терапия Эффективными дозами перораЛЬных диуретиков торасемида (Диувера) и фуросемида в лечении больных с обострением Хронической Сердечной Недостаточности | | |
| КВАНК | КВАдроприл у больных с Недостаточностью Кровообращения, обусловленной ишемической болезнью сердца и дилатационной кардиомиопатией | | |
| КУДЕСНИК | Кудесан® (капли 3% для приема внутрь) в лечении больных с Сердечной Недостаточностью: эффективность И безопасность в Комбинации со стандартной терапией | | |
| ВЫБОР 2 | Лечение пациентов со стабильной ишемической болезнью сердца в клинической практике российских врачей | | |
| НЕМЕЗИДА-ХСН | НЕбиволол против МЕтопролола: сравнительное рандомиЗированное ИсслеДовАние у больных Хронической Сердечной Недостаточностью | | |
| ПРЕАМБУЛА | ПРЕдуктал МВ в АМБУЛАторном лечении больных с сердечной недостаточностью ишемической этиологии. | | |
| РЭМБО-СД ХСН | Рациональная Эффективная Многокомпонентная терапия в БОрьбе с Сахарным Диабетом у больных ХСН | | |
| ФАСОН | Фармакоэкономическая оценка использования ИАПФ в Амбулаторном лечении больных с СердечнОй Недостаточностью | | |
| ФАГОТ | Фармакоэкономическая оценка использования ингибиторов АПФ в амбулаторном лечении больных с Артериальной Гипертонией Осложненного Течения | | |
| ФАУСТ | Эффективность и безопасность комбинации Фозиноприла и гидрохлортиазида при микроАльбуминурии У больных с Сердечно – сосудисТыми заболеваниями | | |
| САДКО-ХСН | Эффекты длительной терапии ингибитором ангиотензинпревращающего фермента квинаприлом, антагонистом рецепторов к ангиотензину II и комбинацией квинаприла и валсартана у больных с умеренной хронической сердечной недостаточностью | | |
| | ABCD | Appropriate Blood Pressure Control in Diabetes |
| | ACCOMPLISH | Avoiding Cardiovascular Events through Combination Therapy in Patients Living with Systolic Hypertension |
| | ACCORD | Action to Control Cardiovascular Risk in Diabetes |
| | ACCORD-BP | Action to Control Cardiovascular Risk in Diabetes Blood Pressure |
| | ACTIVE I | Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events |
| | ACUITY | Acute Catheterization and Urgent Intervention Triage strategY |
| | ADAPT-DES | Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents |
| | ADVANCE | Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation |
| | AFFIRM | Atrial Fibrillation Follow-up Investigation of Rhythm Management |
| | AIRE | Acute Infarction Ramipril Efficacy |
| | ALDO-DHF | ALDOsterone receptor blockade in Diastolic Heart Failure |
| | ALLHAT | Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial |
| | ALTITUDE | Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints |
| | APPRAISE-2 | APixaban for PRevention of Acute ISchemic Events 2 |
| | ARIC | Atherosclerosis Risk in Communities Study |
| | ARISTOTLE | Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation |
| | ARMYDA | Atorvastatin for Reduction of MYocardial Damage during Angioplasty |
| | ARTS | Arterial Revascularization Therapies Study |
| | ASCOT | Anglo-Scandinavian Cardiac Outcomes Trial |
| | ASCOT-LLA | Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm |
| | ASSERT | Asymptomatic Atrial Fibrillation and Stroke Evaluation in Pacemaker Patients and the Atrial Fibrillation Reduction Atrial Pacing Trial |
| | ATLAS | Assessment of Treatment with Lisinopril and Survival |
| | ATOLL | Acute STEMI Treated with primary angioplasty and intravenous enoxaparin Or UFH to Lower ischemic and bleeding events at short- and Long-term follow-up |
| | AVR | aortic valve replacement (замена аортального клапана) |
| | AWESOME | Angina With Extremely Serious Operative Mortality Evaluation |
| | B-CONVINCED | Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode |
| | BARI 2D | Bypass Angioplasty Revascularization Investigation 2 Diabetes |
| | BEAUTIFUL | Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction |
| | BELIEVE | Bi vs Left Ventricular Pacing: an International Pilot Evaluation on Heart Failure Patients with Ventricular Arrhythmias |
| | BEST | Beta-blocker Evaluation of Survival Trial |
| | BLOCK HF | Biventricular versus Right Ventricular Pacing in Heart Failure Patients with Atrioventricular Block |
| | CAPPP | Captopril Prevention Project |
| | CAPRIE | Clopidogrel versus Aspirin in Patients at Risk of Ischaemic Events |
| | CARDia | Coronary Artery Revascularisation in Diabetes |
| | CARE-HF | Cardiac Resynchronization in Heart Failure Study |
| | CHARISMA | Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance |
| | CHARM | Candesartan in Heart Failure – Assessment of Mortality and Morbidity |
| | CHARM-Preserved | Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction |
| | CIBIS | Cardiac Insufficiency Bisoprolol Study |
| | CIBIS II | Cardiac Insufficiency Bisoprolol Study II |
| | CIBIS III | Cardiac Insufficiency Bisoprolol Study III |
| | COMBAT | Conventional versus biventricular pacing in heart failure and bradyarrhythmia |
| | COMET | Carvedilol Or Metoprolol European Trial |
| | COMFORTABLE AMI | Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction |
| | COMPANION | Comparison of Medical Therapy, Pacing, and Defibrillation in Chronic Heart Failure |
| | CONFIRM-HF | Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency |
| | CONSENSUS | Cooperative North Scandinavian Enalapril Survival Study |
| | CONVINCE | Controlled Onset Verapamil Investigation of Cardiovascular Endpoints |
| | COPERNICUS | Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival |
| | CORONA | Controlled Rosuvastatin Multinational Trial in Heart Failure |
| | COURAGE | Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation |
| | CREDO | Clopidogrel for the Reduction of Events During Observation |
| | CTSU | Clinical Trial Service & Epidemiological Studies Unit (Отдел Клинических и Эпидемиологических исследований в Оксфорде) |
| | CURE | Clopidogrel in Unstable Angina to Prevent Recurrent Events |
| | CURRENT OASIS | Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent Events/Optimal Antiplatelet Strategy for Interventions 7 |
| | DANAMI | DANish trial in Acute Myocardial Infarction |
| | DANISH | Danish Study to Assess the Efficacy of ICDs in Patients with Non-ischemic Systolic Heart Failure on Mortality |
| | DASH | Dietary Approaches to Stop Hypertension |
| | DAVID | Dual Chamber and VVI Implantable Defibrillator |
| | DAVIT II | Danish Verapamil Infarction Trial II |
| | DCCT | Diabetes Control and Complications Trial |
| | DEB-AMI | Drug eluting balloon in acute ST-segment elevation myocardial infarction |
| | DECREASE-HF | Device Evaluation of CONTAK RENEWAL 2 and EASYTRAK 2: Assessment of Safety and Effectiveness in Heart Failure |
| | DIG | Digitalis Investigation Group |
| | DIGAMI | Diabetes Mellitus Insulin-Glucose Infusion in Acute Myocardial Infarction |
| | EDIFY | prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY |
| | ELITE II | The Losartan Heart Failure Survival Study |
| | EMPA REG OUTCOME | Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients |
| | EMPHASIS-HF | Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure |
| | EPHESUS | Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and Survival Study |
| | EUROPA | European Trial on Reduction of Cardiac Events with Perindopril in Patients with Stable Coronary Artery Disease |
| | EVEREST-II | Endovascular Valve Edge-to-Edge Repair Study II |
| | EXCEL | Evaluation of XIENCE versus Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization |
| | ExTRACT-TIMI 25 | Enoxaparin and Thrombolysis Reperfusion for Acute myocardial infarction Treatment - Thrombolysis In Myocardial Infarction 25 |
| | FAIR-HF | Ferinject Assessment in patients with IRon deficiency and chronic Heart Failure |
| | FAME | Fractional Flow Reserve Versus Angiography for Multivessel Evaluation |
| | FAMIS | Fosinopril in Acute Myocardial Infarction Study |
| | FDA | Food and Drug Administration (Американский комитет по контролю за пищевыми продуктами и средствами медицинского назначения) |
| | FFR | fractional flow reserve (фракционный резерв кровотока) |
| | FIRST | Flolan International Randomized Survival Trial |
| | FREEDOM | Future Revascularization Evaluation in Patients with Diabetes Mellitus: Optimal Management of Multivessel Disease |
| | GISSI-AF | Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation |
| | GISSI-HF | Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico – Heart Failure |
| | GISSI-P | Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto miocardico -Prevenzione |
| | GRACE | Global Registry of Acute Coronary Events (Шкала GRACE для стратификации риска пациентов с острым коронарным синдромом) |
| | GREATER-EARTH | Evaluation of resynchronization therapy for heart failure in patients with a QRS duration greater than 120 ms |
| | GUSTO | Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries |
| | HEAAL | Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure |
| | HEAT-PPCI | How Effective Are Antithrombotic Therapies in Primary PCI |
| | HOPE-1 | Heart Outcomes Prevention Evaluation–1 |
| | HOPE-2 | Heart Outcomes Prevention Evaluation–2 |
| | HOPE-3 | Heart Outcomes Prevention Evaluation–3 |
| | HOT | Hypertension Optimal Treatment |
| | INTERHEART | Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries |
| | IONA | Impact of nicorandil in angina |
| | HYVET | Hypertension in the Very Elderly Trial |
| | I-PRESERVE | Irbesartan in heart failure with preserved systolic function |
| | JUPITER | Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin |
| | LESSER-EARTH | Evaluation of resynchronization therapy for heart failure in patients with a QRS duration lower than 120 ms |
| | LIFE | Losartan Intervention For Endpoint reduction in hypertension |
| | MADIT | Multicenter Automatic Defibrillator Implantation Trial |
| | MADIT-II | Multicenter Automatic Defibrillator Implantation Trial II |
| | MADIT-CRT | Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy |
| | MDC | Metoprolol in Dilated Cardiomyopathy Trial Study Group |
| | MERIT-HF | Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure |
| | MICRO-HOPE | Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation (substudy of the HOPE study) |
| | MIRACLE | Multicenter InSync Randomized Clinical Evaluation |
| | MRFIT | Multiple Risk Factor Intervention Trial |
| | NEAT-HFpEF | Nitrate’s Effect on Activity Tolerance in Heart Failure with Preserved Ejection Fraction |
| | NETWORK | Network of General Practitioners and Hospital Physicians Involved in the Study of Low versus High Doses of Enalapril in Patients with Heart Failure |
| | NIDDM | non insulin dependent diabetes mellitus (инсулиннезависимый сахарный диабет0 |
| | OASIS | Optimal Antiplatelet Strategy for Interventions |
| | ONTARGET | Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial |
| | OPTIMAAL | Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarctio |
| | OPTIMIZE-HF | Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure |
| | OVERCOME | preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies |
| | PATH-CHF | Pacing Therapies for Congestive Heart Failure |
| | PARADIGM-HF | Angiotensin-Neprilysin Inhibition versus Enalapril in Heart Failure |
| | PARAGON-HF | Prospective Comparison of ARNI with ARB Global Outcomes in HF With Preserved Ejection Fraction |
| | PARAMOUNT | Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion |
| | PARTNER | Transcatheter versus Surgical Aortic-Valve Replacement in High-Risk Patients |
| | PEACE | Prevention of Events with Angiotensin Converting Enzyme Inhibition |
| | PEECH | Prospective Evaluation of EECP in Congestive Heart Failure |
| | PEP-CHF | Perindopril in elderly people with chronic heart failure |
| | PLATO | PLATelet inhibition and patient Outcomes |
| | PRAISE | Prospective Randomized Amlodipine Survival Evaluation |
| | PREAMI | Perindopril and Remodelling in Elderly with Acute Myocardial Infarction |
| | PRECOMBAT | Premier of Randomized Comparison of Bypass Surgery vs. Angioplasty Using Sirolimus-Eluting Stent in Patients With Left Main Coronary Artery Disease |
| | PREVEND IT | Prevention of Renal and Vascular Endstage Disease Intervention Trial |
| | PREVENT-HF | Preventing ventricular dysfunction in pacemaker patients without advanced heart failure |
| | PRODIGY | PROlonging Dual AntIplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia StudY |
| | PROFESS | Prevention Regimen for Effectively Avoiding Second Strokes |
| | PROGRESS | Preventing Strokes by Lowering Blood Pressure in Patients With Cerebral Ischemia |
| | PROSPECT | Predictors of Response to Cardiac Resynchronization Therapy |
| | PROTECT-AF | Watchman Left Atrial Appendage System for Embolic PROTECTion in Patients with Atrial Fibrillation |
| | Q-SYMBIO | Coenzyme Q10 as adjunctive treatment of chronic heart failure: a randomised, double-blind, multicentre trial with focus on SYMptoms, BIOmarker status (Brain-Natriuretic Peptide [BNP]), and long-term outcome (hospitalisations/mortality) |
| | RACE-II | RAte Control Efficacy in Permanent Atrial Fibrillation: a Comparison between Lenient versus Strict Rate Control II |
| | RAFT | Resynchronization–Defibrillation for Ambulatory Heart Failure Trial |
| | RALES | Randomized Aldactone Evaluation Study |
| | RBBB | right bundle branch block (блокада правой ножки пучка Гиса) |
| | REACH | Reduction of Atherothrombosis for Continued Health Registry |
| | REAL-LATE | Correlation of Clopidogrel Therapy Discontinuation in REAL-world Patients Treated with Drug-Eluting Stent Implantation and Late Coronary Arterial Thrombotic Events |
| | RED-HF | Reduction of Events with Darbepoetin Alfa in Heart Failure |
| | RE-LY | Randomized Evaluation of Long-term anticoagulation therapY: dabigatran vs. warfarin |
| | REPLACE | Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery: a double-blind phase III study of haemostatic therapy |
| | RESET | REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation |
| | RESET SCD | REevaluation of optimal treatment Strategies for prEvenTion of Sudden Cardiac Death in patients with ischemic cardiomyopathy |
| | REVERSE | REsynchronization reVErses Remodeling in Systolic left vEntricular dysfunction |
| | RIETE | Informatizado de la Enfermedad TromboEmbolica venosa registry (Испанский информационный регистр венозной тромбоэмболии) |
| | RIVAL | Radial versus femoral access for Coronary Intervention (лучевой или бедренный доступ при коронарографии) |
| | ROCKET-AF | Rivaroxaban Once daily, oral, direct factor Xa inhibition Compared with vitamin K antagonism for prevention of stroke and Embolism Trial in Atrial Fibrillation |
| | SAVE | Survival and Ventricular Enlargement |
| | SAVOR-TIMI 53 | Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus –Thrombolysis in Myocardial Infarction (TIMI) 53 |
| | SCAAR | Swedish Coronary Angiography and Angioplasty Register (шведский регистр коронарографии и ангиопластики) |
| | SCD-HeFT | Sudden Cardiac Death in Heart Failure Trial |
| | SENIORS | Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure |
| | SHIFT | Systolic Heart failure treatment with the lf inhibitor ivabradine |
| | SHOCK | Early revascularization in acute myocardial infarction complicated by cardiogenic shock |
| | SMILE | Survival of Myocardial Infarction Long-Term Evaluation |
| | SOLVD | Studies of Left Ventricular Dysfunction |
| | SPRINT | Systolic Blood Pressure Intervention Trial |
| | STEEPLE | Safety and Efficacy of Enoxaparin in Percutaneous Coronary Intervention Patients |
| | STICH | Surgical Treatment for Ischemic Heart Failure |
| | STOP-Hypertension | Swedish Trial in Old Patients with Hypertension |
| | STREAM | Strategic Reperfusion Early after Myocardial Infarction |
| | SWEDIC | Swedish Doppler-echocardiographic study |
| | SYNERGY | Superior Yield of the New strategy of Enoxaparin, Revascularization and Glycoprotein IIb/IIIa inhibitors |
| | SYNPACE | Vasovagal SYNcope and PACing |
| | SYNTAX | SYNergy between Percutaneous Coronary Intervention with TAXus and Cardiac Surgery |
| | SYST-CHINA | Systolic hypertension in the elderly: Chinese trial |
| | SYST-EUR | Systolic Hypertension in Europe |
| | TACTICS-TIMI 18 | Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy - Thrombolysis in Myocardial Infarction 18 |
| | TAPAS | Thrombus Aspiration during Percutaneous Coronary Intervention in Acute Myocardial Infarction Study |
| | TARGET | Tirofiban and Reopro Give Similar Efficacy Outcomes Trial |
| | TASTE | Thrombus Aspiration in ST-Elevation Myocardial Infarction in Scandinavia |
| | TIMACS | timing of Intervention in acute coronary syndromes (время вмешательства при острых коронарных синдромах) |
| | TIME | Trial of invasive versus medical therapy in elderly patients with chronic symptomatic coronary-artery disease |
| | TOPCAT | Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function |
| | TORIC | TOrasemide In Congestive Heart Failure |
| | TRACE | TRAndolapril Cardiac Evaluation |
| | TRANSCEND | Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease |
| | TRIGGER-PCI | Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel |
| | TRITON TIMI-38 | TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction |
| | UKPDS | United Kingdom Prospective Diabetes Study |
| | UKSAT | UK Small Aneurysm Trial |
| | United States NHDS | United States National Hospital Discharge Survey (национальное исследование выписки пациентов из стационаров США) |
| | USCP | United States carvedilol programme |
| | Val-HeFT | Valsartan Heart Failure Trial |
| | VALIANT | VALsartan In Acute myocardial iNfarcTion |
| | VALUE | Valsartan Antihypertensive Long-term Use Evaluation |
| | V-HeFT I | Vasodilator Heart Failure Trial I |
| | V-HeFT II | Vasodilator Heart Failure Trial II |
| | VISION | Vascular events In noncardiac Surgery patIents cOhort evaluatioN |
| | WARCEF | Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction |
| | WARSS | Warfarin-Aspirin Recurrent Stroke Study |
| | WOEST | What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing |
| | ZEST-LATE | Evaluation of the Long-term Safety After Zotarolimus-Eluting Stent, Sirolimus-Eluting Stent, or PacliTaxel-Eluting Stent Implantation for Coronary Lesions - Late Coronary Arterial Thrombotic Events |
